Oral vitamin E in reducing mucocutaneous side effects of Isotretinoin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138905022085N4

Enrollment

Registered

2010-07-24

Start date

2004-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acne vulgaris. Acne vulgaris

Interventions

Intervention 1: Isotretinoin, 0.5-1 mg/kg/day, as well as 800 IU/day vitamin E for 6 weeks. Intervention 2: Isotretinoin, 0.5-1 mg/kg/day, as well as placebo for 6 weeks.

Treatment - Drugs

Placebo

Isotretinoin, 0.5-1 mg/kg/day, as well as 800 IU/day vitamin E for 6 weeks

Isotretinoin, 0.5-1 mg/kg/day, as well as placebo for 6 weeks

Eligibility

Sex/Gender

All

Age

15 Years to 39 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: suffering from Acne vulgaris, indication of treatment with Isotretinoin Exclusion criteria: age lesser than 15 years old, pregnancy, breast feeding

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mucocutaneous side effects of Isotretinoin. Timepoint: After 4 and 6 weeks. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026